Product Monograph Template - Schedule D
... time of immunization. It is not known whether HAVRIX® will prevent hepatitis A in such cases. Since there is a possibility that the vaccine may contain trace amounts of neomycin, the possibility of an allergic reaction in individuals sensitive to this substance should be kept in mind when considerin ...
... time of immunization. It is not known whether HAVRIX® will prevent hepatitis A in such cases. Since there is a possibility that the vaccine may contain trace amounts of neomycin, the possibility of an allergic reaction in individuals sensitive to this substance should be kept in mind when considerin ...
Low hepatitis B immunogenicity of a hexavalent vaccine widely used
... a secondary data analysis of a large cross-sectional health survey in Germany. On average 2.4 years after vaccination, 25.3 % of Hexavac vaccinees had anti-HBs levels <10 mIU/ml (95 % CI 19.0–32.8) compared to 4.7 % of Infanrix hexa vaccinees (95 % CI 2.4–8.9). These findings suggest that short-term ...
... a secondary data analysis of a large cross-sectional health survey in Germany. On average 2.4 years after vaccination, 25.3 % of Hexavac vaccinees had anti-HBs levels <10 mIU/ml (95 % CI 19.0–32.8) compared to 4.7 % of Infanrix hexa vaccinees (95 % CI 2.4–8.9). These findings suggest that short-term ...
Vaccination of healthcare workers
... This guideline provides information to support Queensland Health in the development and implementation of a workforce vaccination program in accordance with national guidelines and the Queensland Health Health employment directive: Vaccine Preventable Diseases (VPD) requirements and Health service d ...
... This guideline provides information to support Queensland Health in the development and implementation of a workforce vaccination program in accordance with national guidelines and the Queensland Health Health employment directive: Vaccine Preventable Diseases (VPD) requirements and Health service d ...
Human Papillomavirus: What you should know
... A. Yes. Because the HPV vaccine is made using only a single protein from each type of the virus, it can’t cause HPV and, therefore, can’t cause cervical cancer or other cancers. The most common side effect of the vaccine is redness and tenderness at the injection site. The vaccine may also cause a s ...
... A. Yes. Because the HPV vaccine is made using only a single protein from each type of the virus, it can’t cause HPV and, therefore, can’t cause cervical cancer or other cancers. The most common side effect of the vaccine is redness and tenderness at the injection site. The vaccine may also cause a s ...
Post Vaccination Evaluation of Anti-HBsAg Antibody Titers
... Research previously has noted that few vaccinated population (chronic liver/kidney diseases, immunodeficiency due to HIV infection, diabetes mellitus, etc) failed to produce adequate anti-HBsAg antibody titers and are termed as non/poor/hypo-responders. Studies in the past have also reviewed the nec ...
... Research previously has noted that few vaccinated population (chronic liver/kidney diseases, immunodeficiency due to HIV infection, diabetes mellitus, etc) failed to produce adequate anti-HBsAg antibody titers and are termed as non/poor/hypo-responders. Studies in the past have also reviewed the nec ...
Pertussis Fact Sheet
... dTpa vaccine is recommended for any adult who wishes to reduce the likelihood of becoming ill with pertussis, but is particularly important for adults who meet the criteria of a special risk group (see below). dTpa vaccine should be used in place of dT vaccine at the age routinely recommended for a ...
... dTpa vaccine is recommended for any adult who wishes to reduce the likelihood of becoming ill with pertussis, but is particularly important for adults who meet the criteria of a special risk group (see below). dTpa vaccine should be used in place of dT vaccine at the age routinely recommended for a ...
Pertussis vaccines for Australians
... dTpa vaccine is recommended for any adult who wishes to reduce the likelihood of becoming ill with pertussis, but is particularly important for adults who meet the criteria of a special risk group (see below). dTpa vaccine should be used in place of dT vaccine at the age routinely recommended for a ...
... dTpa vaccine is recommended for any adult who wishes to reduce the likelihood of becoming ill with pertussis, but is particularly important for adults who meet the criteria of a special risk group (see below). dTpa vaccine should be used in place of dT vaccine at the age routinely recommended for a ...
Preliminary Programme
... New infectious diseases are a continuing threat to mankind. These are often caused by animal viruses that have or have acquired the ability to infect humans, followed by human-to-human transmission (e.g. SARS, MERS, Ebola and several influenza A subtypes). Such infections are potentially devastating ...
... New infectious diseases are a continuing threat to mankind. These are often caused by animal viruses that have or have acquired the ability to infect humans, followed by human-to-human transmission (e.g. SARS, MERS, Ebola and several influenza A subtypes). Such infections are potentially devastating ...
defending ontario against
... Receiving two doses of vaccine is a free and very effective form of protection against the virus both for individuals and the community. Since the two-dose vaccine was introduced in Ontario in 1996, very few cases of measles have been reported each year. ...
... Receiving two doses of vaccine is a free and very effective form of protection against the virus both for individuals and the community. Since the two-dose vaccine was introduced in Ontario in 1996, very few cases of measles have been reported each year. ...
35. Thanee C. et al. The immunogenicity and safety of
... vaccine conjugated with diphtheria toxoid (PCV7) is approved in Europe since 2001 and is effective in reducing incidence of invasive disease by vaccine serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), in both children and adults, due to effect of herd immunity. A PCV13 formulation has recently been develop ...
... vaccine conjugated with diphtheria toxoid (PCV7) is approved in Europe since 2001 and is effective in reducing incidence of invasive disease by vaccine serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), in both children and adults, due to effect of herd immunity. A PCV13 formulation has recently been develop ...
Feline Panleukopenia Vaccine
... tor to determine when revaccination may be needed.1,2 For other diseases, a serological response has not been identified that correlates with protection. Practical knowledge of the disease, the vaccine and the patient, along with serologic test results when appropriate, is paramount in making the be ...
... tor to determine when revaccination may be needed.1,2 For other diseases, a serological response has not been identified that correlates with protection. Practical knowledge of the disease, the vaccine and the patient, along with serologic test results when appropriate, is paramount in making the be ...
Classification of Vaccines
... World War II more systematic childhood vaccination programs became a widespread tool for improving public health (Bloom et al. 2005). The mortality caused by serious and life-threatening diseases has been dramatically reduced as a result of these successful global childhood vaccination programs, and ...
... World War II more systematic childhood vaccination programs became a widespread tool for improving public health (Bloom et al. 2005). The mortality caused by serious and life-threatening diseases has been dramatically reduced as a result of these successful global childhood vaccination programs, and ...
Measles - Government of Nova Scotia
... travelling/health-safety/travel-health-notices/measles, the vaccine may be given as early as six months of age. Under these circumstances, the routine two dose series must be then restarted on or after the first birthday, for a total of three doses. 2. Adolescents and Adults: • Adults born in or af ...
... travelling/health-safety/travel-health-notices/measles, the vaccine may be given as early as six months of age. Under these circumstances, the routine two dose series must be then restarted on or after the first birthday, for a total of three doses. 2. Adolescents and Adults: • Adults born in or af ...
A guide to vaccinations at three years and four months of age
... If your child has not had an MMR vaccination before, they should have the first dose now and the second dose after one month. Two doses of the MMR vaccine are routinely given across Europe as well as in the US, Canada, Australia and New Zealand. By giving your child a second dose of the MMR vaccine ...
... If your child has not had an MMR vaccination before, they should have the first dose now and the second dose after one month. Two doses of the MMR vaccine are routinely given across Europe as well as in the US, Canada, Australia and New Zealand. By giving your child a second dose of the MMR vaccine ...
4.3 Haemophilus influenzae type b
... recommendations for Hib vaccine choice (refer to 3.1 Vaccination for Aboriginal and Torres Strait Islander people). There have been four distinct eras of implementation of the Hib vaccination program for Australian children, which are described in detail elsewhere.10 Some Hib combination vaccines co ...
... recommendations for Hib vaccine choice (refer to 3.1 Vaccination for Aboriginal and Torres Strait Islander people). There have been four distinct eras of implementation of the Hib vaccination program for Australian children, which are described in detail elsewhere.10 Some Hib combination vaccines co ...
duration of virus shedding after trivalent intranasal live attenuated
... vaccinees to non-immune, high-risk individuals. As a result, FluMist was not recommended for use in immunocompromised individuals,6 and vaccine recipients were strongly advised to avoid close contact with immunocompromised individuals for at least 21 days after vaccination.6 Due to this advisor y, s ...
... vaccinees to non-immune, high-risk individuals. As a result, FluMist was not recommended for use in immunocompromised individuals,6 and vaccine recipients were strongly advised to avoid close contact with immunocompromised individuals for at least 21 days after vaccination.6 Due to this advisor y, s ...
Pneumococcal Vaccination Resources
... FDA expands use of the pneumococcal conjugate vaccine Prevnar 13 for people age 50 and older On December 30, 2011, FDA issued a press release announcing that it has approved the use of the pneumococcal 13-valent conjugate vaccine, Prevnar 13 [Wyeth Pharmaceuticals], to prevent pneumonia and invasive ...
... FDA expands use of the pneumococcal conjugate vaccine Prevnar 13 for people age 50 and older On December 30, 2011, FDA issued a press release announcing that it has approved the use of the pneumococcal 13-valent conjugate vaccine, Prevnar 13 [Wyeth Pharmaceuticals], to prevent pneumonia and invasive ...
Overview of animal models in vaccine testing
... – Single dose testing generally not needed ● Relevant animal species/strain – Rat – Rabbit (because of im administration?) – Immune response sufficient as criterium, or should the species be sensitive to the disease? ● Dosing schedule – What is the origin of N+1? – Is this useful after 3-4 injection ...
... – Single dose testing generally not needed ● Relevant animal species/strain – Rat – Rabbit (because of im administration?) – Immune response sufficient as criterium, or should the species be sensitive to the disease? ● Dosing schedule – What is the origin of N+1? – Is this useful after 3-4 injection ...
COMMITTEE ON INFECTIOUS DISEASES ; originally published online September 2, 2013; Pediatrics
... home and communicate their immunization status to their primary care provider. Immunization of close contacts of children at high risk of influenza-related complications is ...
... home and communicate their immunization status to their primary care provider. Immunization of close contacts of children at high risk of influenza-related complications is ...
Flu Facts
... Flu viruses spread mainly from person to person through the coughing or sneezing of people with influenza. Sometimes people may become infected by touching something with flu viruses on it and then touching their mouth or nose. Most healthy adults may be able to infect others beginning one day befor ...
... Flu viruses spread mainly from person to person through the coughing or sneezing of people with influenza. Sometimes people may become infected by touching something with flu viruses on it and then touching their mouth or nose. Most healthy adults may be able to infect others beginning one day befor ...
Document
... From thc expression off", the probability that a bite fiom a susceptible mosquito to a human with infectious gametoc],t€s leads to iufection ofthe mosquito. The pammeter smodels the efficacy of the transmission blocking vaccine subunit with r€l0,ll. It d€termines th€ effectiveness in reducing transm ...
... From thc expression off", the probability that a bite fiom a susceptible mosquito to a human with infectious gametoc],t€s leads to iufection ofthe mosquito. The pammeter smodels the efficacy of the transmission blocking vaccine subunit with r€l0,ll. It d€termines th€ effectiveness in reducing transm ...
Bloodborne Pathogen and Biosafety Training Supervisors Training Materials Training Time: Agenda:
... a) can survive outdoors for weeks b) are found in human blood, can cause serious diseases in human and can be transmitted through exposure to blood of an infected individual c) are spread person to person through contaminated water supplies d) do not cause serious disease and are never lethal 3. At ...
... a) can survive outdoors for weeks b) are found in human blood, can cause serious diseases in human and can be transmitted through exposure to blood of an infected individual c) are spread person to person through contaminated water supplies d) do not cause serious disease and are never lethal 3. At ...
Rapid Emergence of Free-Riding Behavior in New Pediatric
... may choose to vaccinate at high rates due to the initial persistence of endemic infection in the population, it is not clear what strategy later birth cohorts will adopt, or when. This question is very topical given the large number of new generation vaccines that have been introduced in recent year ...
... may choose to vaccinate at high rates due to the initial persistence of endemic infection in the population, it is not clear what strategy later birth cohorts will adopt, or when. This question is very topical given the large number of new generation vaccines that have been introduced in recent year ...
Chickenpox - Children`s Hospital of Philadelphia
... Q. How is the chickenpox vaccine made? Q. What are the symptoms of chickenpox? A. People with chickenpox usually have fever, a rash that starts on the head and spreads to the rest of the body, and itching. A typical person will have 300 to 500 blisters which appear in phases, so that not all blister ...
... Q. How is the chickenpox vaccine made? Q. What are the symptoms of chickenpox? A. People with chickenpox usually have fever, a rash that starts on the head and spreads to the rest of the body, and itching. A typical person will have 300 to 500 blisters which appear in phases, so that not all blister ...